We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Single-sex Controlled Human Schistosomiasis Infection: Safety and Dose Finding

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02755324
Recruitment Status : Completed
First Posted : April 28, 2016
Last Update Posted : November 18, 2020
Information provided by (Responsible Party):
Meta Roestenberg, Leiden University Medical Center

Brief Summary:
Groups of 3 or 7 volunteers will be exposed to a predetermined number of male Schistosoma mansoni cercariae until 10 volunteers are found infected.

Condition or disease Intervention/treatment Phase
Schistosomiasis Schistosoma Mansoni Biological: male Schistosoma mansoni cercariae Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 17 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Establishing a Single-sex Controlled Human Schistosomiasis Infection Model: Safety and Dose Finding
Actual Study Start Date : October 27, 2016
Actual Primary Completion Date : July 19, 2018
Actual Study Completion Date : January 21, 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Intervention
Volunteers will be exposed to escalating doses of male Schistosoma mansoni cercariae
Biological: male Schistosoma mansoni cercariae
Viable male Schistosoma mansoni cercariae of the Puerto Rican strain

Primary Outcome Measures :
  1. Number of grade 3 and 4 adverse events, possibly, probably or definitely related to controlled human Schistosoma mansoni infection with male cercariae. [ Time Frame: 20 weeks ]
  2. The number of male cercariae at which 100% volunteers show detectable Schistosoma mansoni circulating anodic antigen (CAA). [ Time Frame: 12 weeks ]

Secondary Outcome Measures :
  1. Average number of weeks until positive serum circulating anodic antigen test [ Time Frame: 12 weeks ]
  2. Comparison of the height of the peak serum circulating anodic antigen concentration in low dose compared with high dose group [ Time Frame: 12 weeks ]
  3. Comparison of the humoral (antibody) response profile by protein and glycan array between infected and uninfected individuals [ Time Frame: 1 year ]
  4. Differences in in ex vivo lymphocyte profiles between infected and uninfected individuals [ Time Frame: 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Subject is aged ≥ 18 and ≤ 45 years and in good health.
  2. Subject has adequate understanding of the procedures of the study and agrees to abide strictly thereby.
  3. Subject is able to communicate well with the investigator, is available to attend all study visits.
  4. Subject will remain within Europe (excluding Corsica) during the study period and is reachable by mobile telephone from week 3 to week 12 of the study period.
  5. Subject agrees to refrain from blood donation throughout the study period.
  6. For female subjects: subject agrees to use adequate contraception and not to breastfeed for the duration of study.
  7. Subject has signed informed consent.

Exclusion Criteria:

  1. Any history, or evidence at screening, of clinically significant symptoms, physical signs or abnormal laboratory values suggestive of systemic conditions, such as cardiovascular, pulmonary, renal, hepatic, neurological, dermatological, endocrine, malignant, haematological, infectious, immune-deficient, psychiatric and other disorders, which could compromise the health of the volunteer during the study or interfere with the interpretation of the study results. These include, but are not limited to, any of the following:

    • body weight <50 kg or Body Mass Index (BMI) <18.0 or >30.0 kg/m2 at screening;
    • positive HIV, hepatitis B or hepatitis C screening tests;
    • the use of immune modifying drugs within three months prior to study onset (inhaled and topical corticosteroids and oral anti-histamines exempted) or expected use of such during the study period;
    • history of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years;
    • any history of treatment for severe psychiatric disease by a psychiatrist in the past year;
    • history of drug or alcohol abuse interfering with normal social function in the period of one year prior to study onset.
    • Any clinically significant abnormalities (including extended QT interval) on electrocardiogram
  2. The chronic use of any drug known to interact with praziquantel, or artesunate or lumefantrine metabolism (e.g. phenytoin, carbamazepine, phenobarbital, primidon, dexamethasone, rifampicin, cimetidine, flecainide, metoprolol, imipramine, amitriptyline, clomipramine, class I and III anti-arrythmics, antipsychotics, antidepressants, macrolides, fluoroquinolones, imidazole- and triazole antimycotics, antihistamines) Because lumefantrine may cause extension of QT-time, chronic use of drugs with effect on QT interval are excluded from the study.
  3. For female subjects: positive urine pregnancy test at screening.
  4. Any history of schistosomiasis or treatment for schistosomiasis.
  5. Positive serology for schistosomiasis or elevated serum or urine circulating anodic antigen or positive Schistosoma serology at baseline.
  6. Known hypersensitivity to or contra-indications (including co-medication) for use of praziquantel or, artesunate or lumefantrine.
  7. Being an employee or student of the department of parasitology or infectious diseases of the Leiden University Medical Center.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02755324

Layout table for location information
Leiden University Medical Center
Leiden, Netherlands, 2333 ZA
Sponsors and Collaborators
Leiden University
Layout table for investigator information
Principal Investigator: Meta Roestenberg LUMC
Publications of Results:
Layout table for additonal information
Responsible Party: Meta Roestenberg, MD, PhD, Leiden University Medical Center
ClinicalTrials.gov Identifier: NCT02755324    
Other Study ID Numbers: CoHSI1
First Posted: April 28, 2016    Key Record Dates
Last Update Posted: November 18, 2020
Last Verified: November 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Trematode Infections
Parasitic Diseases
Vector Borne Diseases